BIOMAT Database Logo BIOMAT Database Logo

Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. 2010

Vsevolod Katritch, and Veli-Pekka Jaakola, and J Robert Lane, and Judy Lin, and Adriaan P Ijzerman, and Mark Yeager, and Irina Kufareva, and Raymond C Stevens, and Ruben Abagyan
Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA. vkatritch@ucsd.edu

The recent progress in crystallography of G-protein coupled receptors opens an unprecedented venue for structure-based GPCR drug discovery. To test efficiency of the structure-based approach, we performed molecular docking and virtual ligand screening (VLS) of more than 4 million commercially available "drug-like" and ''lead-like'' compounds against the A(2A)AR 2.6 A resolution crystal structure. Out of 56 high ranking compounds tested in A(2A)AR binding assays, 23 showed affinities under 10 microM, 11 of those had sub-microM affinities and two compounds had affinities under 60 nM. The identified hits represent at least 9 different chemical scaffolds and are characterized by very high ligand efficiency (0.3-0.5 kcal/mol per heavy atom). Significant A(2A)AR antagonist activities were confirmed for 10 out of 13 ligands tested in functional assays. High success rate, novelty, and diversity of the chemical scaffolds and strong ligand efficiency of the A(2A)AR antagonists identified in this study suggest practical applicability of receptor-based VLS in GPCR drug discovery.

UI MeSH Term Description Entries
D007313 Insecta Members of the phylum ARTHROPODA composed or organisms characterized by division into three parts: head, thorax, and abdomen. They are the dominant group of animals on earth with several hundred thousand different kinds. Three orders, HEMIPTERA; DIPTERA; and SIPHONAPTERA; are of medical interest in that they cause disease in humans and animals. (From Borror et al., An Introduction to the Study of Insects, 4th ed, p1). Insects,Insect
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009281 Naphthalenes Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Vsevolod Katritch, and Veli-Pekka Jaakola, and J Robert Lane, and Judy Lin, and Adriaan P Ijzerman, and Mark Yeager, and Irina Kufareva, and Raymond C Stevens, and Ruben Abagyan
The discovery and synthesis of novel adenosine receptor (A(2A)) antagonists.
March 2005, Bioorganic & medicinal chemistry letters,
Vsevolod Katritch, and Veli-Pekka Jaakola, and J Robert Lane, and Judy Lin, and Adriaan P Ijzerman, and Mark Yeager, and Irina Kufareva, and Raymond C Stevens, and Ruben Abagyan
Discovery of 2-aminoimidazopyridine adenosine A(2A) receptor antagonists.
November 2010, Bioorganic & medicinal chemistry letters,
Vsevolod Katritch, and Veli-Pekka Jaakola, and J Robert Lane, and Judy Lin, and Adriaan P Ijzerman, and Mark Yeager, and Irina Kufareva, and Raymond C Stevens, and Ruben Abagyan
Antiparkinsonian effects of novel adenosine A(2A) receptor antagonists.
January 2011, Archiv der Pharmazie,
Vsevolod Katritch, and Veli-Pekka Jaakola, and J Robert Lane, and Judy Lin, and Adriaan P Ijzerman, and Mark Yeager, and Irina Kufareva, and Raymond C Stevens, and Ruben Abagyan
Discovery of aminoquinazoline derivatives as human A(2A) adenosine receptor antagonists.
February 2016, Bioorganic & medicinal chemistry letters,
Vsevolod Katritch, and Veli-Pekka Jaakola, and J Robert Lane, and Judy Lin, and Adriaan P Ijzerman, and Mark Yeager, and Irina Kufareva, and Raymond C Stevens, and Ruben Abagyan
Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design.
March 2012, Journal of medicinal chemistry,
Vsevolod Katritch, and Veli-Pekka Jaakola, and J Robert Lane, and Judy Lin, and Adriaan P Ijzerman, and Mark Yeager, and Irina Kufareva, and Raymond C Stevens, and Ruben Abagyan
Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists.
July 2013, Journal of chemical information and modeling,
Vsevolod Katritch, and Veli-Pekka Jaakola, and J Robert Lane, and Judy Lin, and Adriaan P Ijzerman, and Mark Yeager, and Irina Kufareva, and Raymond C Stevens, and Ruben Abagyan
Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.
April 2011, Expert opinion on drug metabolism & toxicology,
Vsevolod Katritch, and Veli-Pekka Jaakola, and J Robert Lane, and Judy Lin, and Adriaan P Ijzerman, and Mark Yeager, and Irina Kufareva, and Raymond C Stevens, and Ruben Abagyan
Identification of novel adenosine A(2A) receptor antagonists by virtual screening.
March 2012, Journal of medicinal chemistry,
Vsevolod Katritch, and Veli-Pekka Jaakola, and J Robert Lane, and Judy Lin, and Adriaan P Ijzerman, and Mark Yeager, and Irina Kufareva, and Raymond C Stevens, and Ruben Abagyan
Discovery of novel GPVI receptor antagonists by structure-based repurposing.
January 2014, PloS one,
Vsevolod Katritch, and Veli-Pekka Jaakola, and J Robert Lane, and Judy Lin, and Adriaan P Ijzerman, and Mark Yeager, and Irina Kufareva, and Raymond C Stevens, and Ruben Abagyan
3D pharmacophore based virtual screening of A 2A adenosine receptor antagonists.
March 2010, Protein and peptide letters,
Copied contents to your clipboard!